Unsealed 188Rhenium Resin Brachytherapy in Non-Surgical Candidates With Refractory Basal Cell Carcinoma: Clinical Outcomes
Dermatology Practical & Conceptual · 30.04.2025 · 15 (2) · 4993
DOI: 10.5826/dpc.1502a4993 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology Practical & Conceptual, online erschienen am 30.04.2025. Verfasst von Marco Adriano Chessa und 14 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Introduction
High-dose brachytherapy using a non-sealed 188Rhenium resin (188Re) is a new treatment option for difficult-to-treat basal cell carcinoma (BCC), that ensures a radical oncological outcome minimizing side effects.
Objectives
The aim of this retrospective study is to evaluate the clinical efficacy of high-dose standardized brachytherapy using an unsealed 188Re in the management of difficult-to-treat BCCs and to evaluate the risk factors of relapses.
Methods
Between October 2017 and December 2022, patients affected by difficult-to-treat BCC were selected. Inclusion criteria: histologically proven cutaneous BCC; thickness invasion not deeper than 3 mm; lesion located in the scalp, face, ears, or fingers or other areas in which surgery would have been difficult to perform or to destroy with scarce cosmetic-functional result; and contraindication or refusal of surgery. All patients performed follow-up visits with videodermoscopy every 4-6 months.
Results
Sixty-four consecutive patients, affected by 82 histologically proven high-risk BCCs, were enrolled: 60 were nodular, 9 sclerodermiform, and 13 superficial. Average follow-up was 24 months. Brachytherapy with 188Re healed 93% of difficult-to-treat BCCs with an average time to relapse of 24 months. No statistically significant differences in response to brachytherapy were found in the anatomical area treated, size of the tumor, or previously treated vs. naive BCCs. The sclerodermiform histotype has a 7-fold higher risk of recurrence than nodular histotype; recurrence occurring approximately 12 weeks earlier.
Conclusion
High-dose 188Re brachytherapy is a noninvasive, easy to perform, and tolerable approach to treat difficult BCC when surgery or other therapy techniques are not feasible.
Zitieren
APA
Chessa, M. A., Baraldi, C., Savoia, F., Maltoni, L., Clarizio, G., Filippi, F., Piraccini, B. M., Dika, E., Pitino, A., Tripepi, G., Zagni, F., Strigari, L., Vetrone, L., Fanti, S., & Castellucci, P. (2025). Unsealed 188Rhenium Resin Brachytherapy in Non-Surgical Candidates With Refractory Basal Cell Carcinoma: Clinical Outcomes. Dermatology Practical & Conceptual, 15(2), 4993. https://doi.org/10.5826/dpc.1502a4993
Vancouver
Chessa MA, Baraldi C, Savoia F, Maltoni L, Clarizio G, Filippi F, et al. Unsealed 188Rhenium Resin Brachytherapy in Non-Surgical Candidates With Refractory Basal Cell Carcinoma: Clinical Outcomes. Dermatology Practical & Conceptual. 2025;15(2):4993. doi:10.5826/dpc.1502a4993
BibTeX
@article{Chessa2025,
author = {Chessa, Marco Adriano and Baraldi, Carlotta and Savoia, Francesco and Maltoni, Lorenzo and Clarizio, Giacomo and Filippi, Federica and Piraccini, Bianca Maria and Dika, Emi and Pitino, Annalisa and Tripepi, Giovanni and Zagni, Federico and Strigari, Lidia and Vetrone, Luigia and Fanti, Stefano and Castellucci, Paolo},
title = {Unsealed 188Rhenium Resin Brachytherapy in Non-Surgical Candidates With Refractory Basal Cell Carcinoma: Clinical Outcomes},
journal = {Dermatology Practical & Conceptual},
year = {2025},
volume = {15},
number = {2},
pages = {4993},
doi = {10.5826/dpc.1502a4993}
}
EUVIMED